Interpace Diagnostics Group, Inc.
(NASDAQ : IDXG)

( )
IDXG PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
ESRXExpress Scripts Holding Company
-0.41%96.486.0%$315.19m
ATHNathenahealth, Inc.
0.01%131.5717.7%$174.49m
LHLaboratory Corporation of America Holdings
-0.33%163.892.3%$144.67m
CERNCerner Corporation
0.16%56.507.5%$131.85m
DGXQuest Diagnostics Incorporated
-0.37%94.694.2%$129.71m
SRCLStericycle, Inc.
0.35%45.456.7%$58.99m
HCSGHealthcare Services Group, Inc.
-0.10%42.266.7%$34.73m
OMCLOmnicell, Inc.
-1.00%69.1911.0%$27.88m
MDRXAllscripts Healthcare Solutions, Inc.
0.00%9.909.7%$26.98m
HMSYHMS Holdings Corp.
0.20%35.941.9%$26.05m
HSTMHealthStream, Inc.
-0.32%24.736.7%$4.97m
CPSIComputer Programs and Systems, Inc.
-1.51%25.3832.9%$4.35m
IDXGInterpace Diagnostics Group, Inc.
-19.86%1.173.3%$0.36m
PMDPsychemedics Corporation
0.39%18.230.7%$0.21m
PLXProtalix Biotherapeutics, Inc.
5.90%0.435.8%$0.16m

Company Profile

Interpace Diagnostics Group, Inc. is an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.